Northern Trust Corp Rhythm Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 498,466 shares of RYTM stock, worth $30.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

498,466

Previous 499,448 0.2%

Holding current value

$30.9 Million

Previous $20.5 Million 27.34%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$40.81 - $55.0 $40,075 - $54,010	-982 Reduced 0.2%	498,466 $26.1 Million
Q2 2024 Aug 14, 2024	SELL	$35.41 - $44.37 $120,641 - $151,168	-3,407 Reduced 0.68%	499,448 $20.5 Million
Q1 2024 May 14, 2024	BUY	$39.12 - $52.44 $68,890 - $92,346	1,761 Added 0.35%	502,855 $21.8 Million
Q4 2023 Feb 13, 2024	SELL	$21.39 - $49.64 $62,629 - $145,345	-2,928 Reduced 0.58%	501,094 $23 Million
Q3 2023 Nov 13, 2023	BUY	$15.81 - $27.8 $155,254 - $272,996	9,820 Added 1.99%	504,022 $11.6 Million
Q2 2023 Aug 11, 2023	BUY	$16.32 - $21.15 $5.75 Million - $7.45 Million	352,065 Added 247.69%	494,202 $8.15 Million
Q1 2023 May 15, 2023	BUY	$16.88 - $34.24 $68,127 - $138,192	4,036 Added 2.92%	142,137 $2.54 Million
Q4 2022 Feb 13, 2023	BUY	$22.21 - $30.25 $532,862 - $725,758	23,992 Added 21.03%	138,101 $4.02 Million
Q3 2022 Nov 14, 2022	BUY	$4.3 - $30.85 $12,298 - $88,231	2,860 Added 2.57%	114,109 $2.8 Million
Q2 2022 Aug 12, 2022	SELL	$3.12 - $12.25 $953,590 - $3.74 Million	-305,638 Reduced 73.31%	111,249 $462,000
Q1 2022 May 13, 2022	SELL	$6.13 - $12.24 $74,687 - $149,132	-12,184 Reduced 2.84%	416,887 $4.8 Million
Q4 2021 Feb 08, 2022	BUY	$8.62 - $13.9 $74,450 - $120,054	8,637 Added 2.05%	429,071 $4.28 Million
Q3 2021 Nov 15, 2021	SELL	$11.68 - $20.72 $236,543 - $419,621	-20,252 Reduced 4.6%	420,434 $5.49 Million
Q2 2021 Aug 13, 2021	BUY	$18.52 - $22.55 $106,045 - $129,121	5,726 Added 1.32%	440,686 $8.63 Million
Q1 2021 May 12, 2021	BUY	$20.25 - $39.49 $324,769 - $633,340	16,038 Added 3.83%	434,960 $9.25 Million
Q4 2020 Feb 11, 2021	SELL	$21.17 - $32.61 $294,220 - $453,213	-13,898 Reduced 3.21%	418,922 $12.5 Million
Q3 2020 Nov 16, 2020	SELL	$18.13 - $30.61 $487,751 - $823,500	-26,903 Reduced 5.85%	432,820 $9.38 Million
Q2 2020 Aug 14, 2020	BUY	$14.41 - $25.35 $1.06 Million - $1.86 Million	73,375 Added 18.99%	459,723 $10.3 Million
Q1 2020 May 14, 2020	BUY	$13.16 - $22.9 $302,048 - $525,600	22,952 Added 6.32%	386,348 $5.88 Million
Q4 2019 Feb 14, 2020	BUY	$19.53 - $25.5 $1.37 Million - $1.79 Million	70,310 Added 23.99%	363,396 $8.34 Million
Q3 2019 Nov 13, 2019	BUY	$18.62 - $24.51 $1.46 Million - $1.93 Million	78,588 Added 36.64%	293,086 $6.33 Million
Q2 2019 Aug 13, 2019	SELL	$21.11 - $28.48 $54,210 - $73,136	-2,568 Reduced 1.18%	214,498 $4.72 Million
Q1 2019 May 13, 2019	BUY	$24.76 - $31.66 $153,264 - $195,975	6,190 Added 2.94%	217,066 $5.95 Million
Q4 2018 Feb 12, 2019	SELL	$24.11 - $31.34 $22,132 - $28,770	-918 Reduced 0.43%	210,876 $5.67 Million
Q3 2018 Nov 14, 2018	BUY	$26.99 - $35.85 $1.82 Million - $2.42 Million	67,575 Added 46.86%	211,794 $6.18 Million
Q2 2018 Sep 18, 2018	BUY	$17.02 - $35.2 $216,919 - $448,624	12,745 Added 9.69%	144,219 $4.51 Million
Q2 2018 Aug 14, 2018	BUY	$17.02 - $35.2 $696,560 - $1.44 Million	40,926 Added 45.2%	131,474 $4.11 Million
Q1 2018 May 09, 2018	BUY	$19.9 - $32.25 $246,103 - $398,835	12,367 Added 15.82%	90,548 $1.8 Million
Q4 2017 Feb 14, 2018	BUY	$22.0 - $30.51 $1.72 Million - $2.39 Million	78,181	78,181 $2.27 Million

Others Institutions Holding RYTM

# of Institutions

192

Shares Held

67.3M

Call Options Held

834K

Put Options Held

78.6K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.46B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Rhythm Pharmaceuticals, Inc. Transaction History